linkedin

Financial Snapshot

INCOME STATEMENT

(Unit : KRW million) (Consolidated from 2021)
Income Statement (2018 ~ 2021)
Revenue 2018 2019 2020 2021
CMO 535,806 701,592 1,164,777 1,568,007
Biosimilar 368,734 765,859 777,374 846,977
(Unit : KRW million) (Consolidated from 2021)
Income Statement (2018 ~ 2021)
2019 2020 2021
CMO 701,592 1,164,777 1,568,007
Biosimilar 765,859 777,374 846,977

BALANCE SHEET

(Unit : KRW million) (Consolidated from 2021)
BALANCE SHEET (2018 ~ 2021)
2018 2019 2020 2021
Current Assets 1,577,684 1,356,262 1,751,347 2,823,175
Non-Current Assets 4,402,725 4,555,365 4,672,854 5,146,836
- Total Assets 5,980,409 5,911,627 6,424,201 7,970,011
Current Liabilities 710,530 690,505 589,301 1,107,295
Non-Current Liabilities 1,114,410 866,668 1,236,117 1,871,614
- Total Liabilities 1,824,940 1,557,173 1,825,417 2,978,909
- Total Equities 4,155,468 4,354,454 4,598,783 4,991,102
(Unit : KRW million) (Consolidated from 2021)
BALANCE SHEET (2018 ~ 2021)
2019 2020 2021
Current Assets 1,356,262 1,751,347 2,823,175
Non-Current Assets 4,555,365 4,672,854 5,146,836
Total Assets 5,911,627 6,424,201 7,970,011
Current Liabilities 690,505 589,301 1,107,295
Non-Current Liabilities 866,668 1,236,117 1,871,614
Total Liabilities 1,557,173 1,825,417 2,978,909
Total Equities 4,354,454 4,598,783 4,991,102

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved